Fig. 6

Didymin protects mice against high-fat diet-induced MAFLD by activating Sirt1. A Graphical description of the experimental design of this study. B Body weight (n = 6–8). C Liver weight. D Liver index. E–J Serum level of TG, TC, ALT, AST, LDL and HDL (n = 5–6). K Representative H&E, oil red O, Masson, and PAS staining of hepatic sections (Scale bar = 50 μm). L Transmission electron microscopy figures of hepatocytes, arrows show lipid droplets (Scale bar = 1.2 μm). All values were expressed as the mean ± SD. *P < 0.05, **P < 0.01, ****P < 0.0001 PA vs. PA + Didymin. ^##P < 0.01, ^####P < 0.0001 control vs. MAFLD. PA palmitic acid, MAFLD metabolic associated fatty liver disease, TG triglyceride, TC total cholesterol, ALT alanine aminotransferase, AST aspartate aminotransferase, LDL low-density lipoprotein, HDL high-density lipoprotein, H&E hematoxylin, and eosin